Skip to main content

Table 1 EMICORON increase therapeutic efficacy of FOLFIRI regimen against CRC PDXs

From: Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities

Treatmenta Regressionb Stable diseaseb Progressionb
EMICORON 0/5 1/5 4/5
FOLFIRI 1/5 3/5 1/5
FOLFIRI plus EMICORON 3/5 2/5 0/5
  1. aTumor fragments derived from passage 1, were coated in Matrigel and implanted s.c. in mice (15–20 mm3/mouse) as described in the legend of fig. 2. When the tumor mass reached about 250 to 300 mm3, treatment started by giving mice FOLFIRI regimen consisting in Irinotecan (CPT-11) i.p. at 15 mg/kg for five consecutive days, followed by 5-Fluorouracil (5-FU) i.p. at 19 mg/kg plus Leucovorin at 20 mg/kg for five consecutive days. EMICORON was administered per os at 15 mg/kg for the next seven days. Five mice were included in each experimental group
  2. bRegression or stable disease were considered when was observed the reduction or the maintenance, respectively, of the same tumor weight for at least two weeks after the starting of treatment